The story behind the first AI company valued at $1.8 billion — and the controversies nobody talked about
A class action lawsuit filed in California is putting one of the most celebrated stories in artificial intelligence to the test. What looked like the ultimate example of AI’s transformative power turned out to be something a lot more complicated — and a lot less inspiring than the world was led to believe.
On April 2, 2026, the New York Times published an article that quickly went viral on social media, especially on X, formerly Twitter. The story seemed almost too perfect: a single person had allegedly built Medvi, a company valued at $1.8 billion, in just two months, with only $20,000 out of pocket, no venture capital investors, no team, using basically artificial intelligence tools and a lot of determination.
The most shared post on the topic, published by researcher Yuchen Jin, pretty much summed up the wave of excitement that swept across the tech ecosystem:
One person, two months, $20K initial investment, no VC, vibe-coded software. $1.8 billion company. We are about to see more one-person billion-dollar companies. AI is compressing five years of building, launching, team scaling, and fundraising into one high-execution solo CEO plus two months.
Except there is one detail — and it is not a small one.
Behind the inspiring narrative, there is an investigation by Futurism dating back to May 2025, a detailed analysis published on YouTube by the channel Voidzilla, and a lawsuit with serious accusations of spam, spoofed domains, and practices that allegedly circumvented digital security filters. None of this was covered in any meaningful depth in the article the entire world shared. 👇
What is Medvi and why it became famous overnight
Medvi presents itself as a digital health platform focused on weight loss and longevity treatments. The model connects patients to doctors who prescribe medications like semaglutide — the famous active ingredient in Ozempic and Wegovy, which have become global phenomena over the past two years. The process looks simple on the surface: the user signs up, goes through an online consultation, and gets a prescription, all powered by technology.
On paper, it seems like the kind of company that makes total sense in the moment we are living in. The explosion of GLP-1 medications created massive demand for easier access to weight loss treatments, and telemedicine platforms multiplied to meet that need. Medvi positioned itself in this market with the added promise of being built almost entirely with artificial intelligence, which added a layer of tech fascination to a business model that already had strong commercial appeal on its own.
Receive the best innovation content in your email.
All the news, tips, trends, and resources you're looking for, delivered to your inbox.
By subscribing to the newsletter, you agree to receive communications from Método Viral. We are committed to always protecting and respecting your privacy.
The problem starts when you pull at the threads of this story with a little more care.
The narrative the New York Times helped spread placed Medvi at the center of a much bigger conversation about the power of AI to level the playing field between large corporations and individual entrepreneurs. The idea that a single person, armed with generative artificial intelligence tools and a healthy dose of entrepreneurial vision, managed to build a billion-dollar company in two months resonated deeply with anyone working in tech. It was the kind of story everyone wanted to believe — and that collective desire to believe may have contributed to important questions going unanswered in the first hours of virality.
What very few people read — or at least not with the same attention they gave the NYT article — is that Medvi had already been on the radar of journalistic investigations since May 2025. Futurism, a publication specializing in technology and science, had raised red flags about the company’s customer acquisition practices months before the story went viral. When the Times article dropped, that information already existed — it just was not in the same spotlight. 📰
The class action accusations: spam, spoofed domains, and bypassed filters
The lawsuit filed in California is the heart of this whole story. The class action accuses Medvi of running a large-scale spam operation, directly violating California anti-spam laws. According to court documents, Medvi’s affiliate marketers allegedly used falsified header information, spoofed domains, and nonsensical sender addresses to bypass spam filters and reach users who never consented to receiving those communications.
The technique described is known in the digital security world as domain spoofing combined with domain rotation. In practice, this means the operation would have been creating and discarding sending domains at high speed so that email providers’ spam filtering systems could not block the addresses in time. It is a sophisticated technique that requires dedicated infrastructure and specialized knowledge — which, on its own, already raises questions about the narrative that absolutely everything was built by a single person with no support whatsoever.
On top of that, the lawsuit mentions that the subject lines of the emails sent used deliberately misleading and deceptive language to trick recipients into opening the messages. This kind of practice is not just ethically questionable — it is potentially illegal under the CAN-SPAM Act, the federal U.S. legislation that has regulated the sending of commercial emails in the United States since 2003, as well as under California state laws that provide additional consumer protections.
If the accusations are proven, it means a significant portion of Medvi’s meteoric growth may have been built on illegal customer acquisition practices. And that completely changes the framing of the story: we are no longer talking about a visionary entrepreneur who used artificial intelligence brilliantly, but possibly about an operation that leveraged technology to scale practices that are prohibited by law. 🤔
The Futurism investigation and the YouTube deep dive that came before the viral moment
One of the most frustrating aspects of this story is that information about Medvi’s problems was not new when the New York Times article was published. Futurism had published a detailed investigation in May 2025, nearly a year earlier, examining the connections between Medvi and the online Ozempic prescription market. The report raised questions about the legitimacy of the business model and the marketing tactics employed by the company.
Later, content creator Voidzilla published an analysis on YouTube that was described by multiple observers as brutal and convincing. The video expanded and deepened the investigative work from Futurism, adding technical evidence about email sending patterns, domain variations, and personalization techniques that would be characteristic of automated spam operations at an industrial scale.
Voidzilla’s analysis sparked significant debate within email security and digital marketing communities, especially because the methods described are exactly the kind of thing generative artificial intelligence tools make easier to implement. This adds a layer of irony to the story: the company that became famous for supposedly using AI in an innovative way may have used that same technology to automate practices that break the law.
As Voidzilla pointed out in their conclusions, if the Medvi story proves anything about artificial intelligence, it is not that AI lets you build billion-dollar companies from scratch — it is that AI can be used as a tool for abuse at unprecedented scale. A very different takeaway from the one that went viral on X.
Questions about revenue and the billion-dollar valuation
Another point that deserves attention, and that was raised by sources closely following the case, is the actual truthfulness of the revenue numbers reported by Medvi. The company did not go through a formal investment round that could validate its market valuation through third-party due diligence. There is no public audit of its financials. The $1.8 billion valuation circulated as established fact, but the verification mechanisms that normally accompany figures of that magnitude simply do not exist in this case.
As noted by a source close to the case who has been following the situation for months, Medvi would essentially be a layer of fraud stacked on top of platforms that are already questionable on their own, though possibly less illegal. The same source speculated that if there is real money in the operation, the company will likely be sued by all of its vendors and partners, since it would be in violation of virtually every agreement in terms of regulatory compliance and secure handling of health data.
And perhaps the sharpest observation was this one: if the company is lying about its marketing practices, spoofing domains, and bypassing security filters, why exactly should we believe it is telling the truth about its revenue numbers? It is an uncomfortable question, but an absolutely legitimate one given the context. 📊
What the New York Times left out — and why it matters
The most pointed criticism that circulated after the article went viral was not necessarily about what the New York Times published, but about what was left out. Journalists, researchers, and tech professionals pointed out that the Futurism investigation, the YouTube analysis, and the lawsuit allegations were all public and verifiable information at the time the article was produced.
The editorial choice to build a narrative centered on inspiration and the potential of artificial intelligence without adequately contextualizing the existing controversies around Medvi ended up creating an incomplete picture — and that incomplete picture is exactly what the world shared thousands of times over. People did not share caveats. They shared the headline.
This raises an important discussion about how journalism covers technology stories in an environment where speed of publication and viral potential influence editorial decisions. A billion-dollar company built in two months with AI by a single person is, objectively, a powerful journalistic hook. But when that company was already being investigated for questionable practices and facing a lawsuit, the responsibility to present the full picture becomes even more critical — precisely because stories like this tend to get amplified without any filter by an audience that is, understandably, excited about the possibilities of technology.
The episode also exposes something broader about the information ecosystem in 2026: rigorous investigations that require attention and careful reading compete at a brutal disadvantage against success narratives that are easy to summarize in a post of a few lines. Futurism did the investigative work. The class action was filed publicly. The Voidzilla video was available for anyone to watch. But the right format, in the right outlet, at the right moment, was enough for the most palatable version of the story to completely dominate the attention cycle.
What happens now with Medvi — and what this means for AI
The lawsuit is still ongoing, and the accusations remain allegations until there is a definitive court ruling. Medvi, for its part, did not lose its billion-dollar valuation overnight — the GLP-1-based digital health market is real, the demand is real, and the business model has fundamentals that exist independently of the controversies around marketing practices. What changes is public perception and, potentially, the trust of users and business partners who learned about the allegations for the first time when the class action gained visibility.
For the artificial intelligence ecosystem as a whole, the Medvi case serves as an important reminder that the same tools that allow one person to build a product at scale in record time can also be used to automate practices that exist in gray areas — or are outright illegal — from a legal and ethical standpoint. The narrative of the solo entrepreneur armed with AI is seductive, but it is not immune to the reality that rapid growth, especially in highly regulated sectors like healthcare, attracts proportional scrutiny.
And that scrutiny eventually arrives, whether through investigative journalism, through the courts, or through the very tech community that initially applauded and then started asking tough questions.
As Voidzilla noted in their analysis, Medvi should not be celebrated as the definitive success story of the AI era. If anything, it should be treated as a warning sign — a concrete reminder of how artificial intelligence can be weaponized to scale abusive practices with unprecedented efficiency. That is the opposite of the message the most optimistic technology enthusiasts should want to associate with the future of AI.
How this case unfolds will be closely watched by digital law attorneys, marketing professionals, healthcare regulators, and of course the tech community that first celebrated and then began to question. What remains for now is the certainty that stories that seem too good to be true deserve, at the very least, a second read — preferably before hitting the share button. 👀
